StockData

Yarrow Bioscience, Inc. (YARW) company profile

YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/30102% above fair value
$14.21+0.28 (+2.01%)

Close on Nov 17, 2026Market cap $37.94MP/E –Yield –

About Yarrow Bioscience

Pharmaceutical Preparations, SIC 2834

VYNE is a clinical-stage biopharmaceutical company that develops therapies for inflammatory and immune-mediated conditions with high unmet medical needs. The company focuses on small molecule bromodomain and extra-terminal domain BET inhibitors, specifically through its InhiBET platform. Its pipeline includes VYN202, an oral BD2-selective inhibitor under evaluation for various autoimmune and inflammatory disorders, and repibresib, a topical pan-bromodomain inhibitor. Because its drug candidates remain in clinical development, the company does not yet sell commercial products to end consumers, but its research targets patients afflicted with serious inflammatory conditions.

The company maintains no internal manufacturing facilities and relies entirely on third-party contract organizations to produce materials for preclinical and clinical testing. It holds exclusive global rights to its core BET inhibitor compounds, and its intellectual property encompasses granted patents and pending applications across numerous international jurisdictions, including the United States, Europe, the United Kingdom, Japan, and China. The provided text does not identify the location of the company's corporate headquarters or total employee headcount.

Summary of the business section of Yarrow Bioscience's latest annual report, written by StockData.

Company profile

Company

Legal name
Yarrow Bioscience, Inc.
Headquarters
New Haven, CT
Address
470 James Street, Suite 007 06513
Phone
(203) 433-7577
Employees
10, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Baker Tilly US, LLP, Tewksbury, Massachusetts

Stock & identifiers

Ticker
YARW
Former tickers
VYNE until Jul 28, 2026; MNLO until Sep 8, 2020
Exchange
Nasdaq
IPO date
Jan 26, 2018
Shares outstanding
3M, Aug 10, 2026
Public float
$32.00M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-50 reverse, Jul 27, 2026; 1-for-18 reverse, Feb 13, 2023; 1-for-4 reverse, Feb 16, 2021
SEC CIK
1566044
CUSIP
92941V407
ISIN
US92941V4077
FIGI
BBG00H5W8GM8
Share class FIGI
BBG00H5W8GN7
EIN
45-3757789

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Rebecca FreyChief Executive Officer, Director–
David DomzalskiPRESIDENT AND CEO, Director347,174
Tyler ZerondaChief Financial Officer74,918
Rachael AlfordChief Operating Officer–
Steven RyderChief Medical Officer–
Lori PaytonChief Development Officer–
Mutya HarschCHIEF LEGAL OFFICER AND GC95,918
Iain StuartCHIEF SCIENTIFIC OFFICER95,944
Capital GP X. LLC OrbiMedDirector–
Genesis GP LLC OrbiMedDirector–
Steven L. HoerterDirector–
Advisors Llc OrbimedDirector233,019
Mona AshiyaDirector33,287
Peter B. SilvermanDirector–
William Richard WhiteDirector–
Sven Ante LundbergDirector–
Elisabeth Sandoval LittleDirector–
Steven L. BastaDirector853,942
Patrick G. LeporeDirector51,472
Sharon BarbariDirector75,000
Christine BorowskiDirector–
Anthony D. BrunoDirector120,123

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
David Domzalski
President and Chief Executive Officer
$637.56K$524.25K$436.50K$361.50K$13.80K$1.97M-27%
Iain Stuart
Chief Scientific Officer
$455.56K$145.63K$121.25K$172.20K$13.80K$908.43K-22%
Mutya Harsch
Chief Legal Officer, General Counsel and Secretary
$443.28K$145.63K$121.25K$167.56K$13.80K$891.52K-21%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 26, 2018
Offer price
$17.00
Securities offered
7,000,000
Gross proceeds
$119.00M
Exchange
Nasdaq
First trading day
Jan 25, 2018
First-day close
$28.71+68.9%
Lock-up ends (est.)
Jul 24, 2018

“The initial public offering price is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had a total of 10 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 28, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 24, 2026Name changeName changed from VYNE Therapeutics Inc. to Yarrow Bioscience, Inc.
Mar 31, 2026MergerRegistration of securities for a merger or exchange offer (S-4)
Mar 11, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 12, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 30, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 7, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 4, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 13, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 2, 2020Name changeName changed from Menlo Therapeutics Inc. to VYNE Therapeutics Inc.
Jun 10, 2020Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 6, 2020Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 10, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 4, 2019MergerRegistration of securities for a merger or exchange offer (S-4)
Jan 26, 2018IPOInitial public offering priced (424B4 prospectus)
Jan 19, 2018ListingRegistration of securities on an exchange (Form 8-A)
Jan 7, 2013Name changeName changed from Tigercat Pharma, Inc. to Menlo Therapeutics, Inc.

See a number that looks wrong?